<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81981">
  <stage>Registered</stage>
  <submitdate>24/04/2007</submitdate>
  <approvaldate>30/04/2007</approvaldate>
  <actrnumber>ACTRN12607000226404</actrnumber>
  <trial_identification>
    <studytitle>A double-blind cross-over placebo controlled study of Evogen® Topical gel in the treatment of mild to moderate pain associated with osteoarthritis</studytitle>
    <scientifictitle>Participants: Osteoarthritis of the knees
Intervention: Evogen® Topical gel
Comparator: Placebo 
Outcome: Reduction in VAS pain scale scores</scientifictitle>
    <utrn />
    <trialacronym>N/A</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Mild to moderate pain in osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Evogen® Topical gel (nutraceutical) 4 cc to be applied externally to the affected area every 6 hours for 1 week.  Placebo dose protocol the same.  Participants will use one treatment in the first week of the study, washout for 2 weeks then apply the other treatment for a further 7 days.</interventions>
    <comparator>Placebo is applied externally to the affected area every 6 hours for 1 week.  Placebo will be manufactured from the same exipient base.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in VAS pain scale scores</outcome>
      <timepoint>Measured 3 times on day 1 then once daily for a further 6 days.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>COAT (Comprehensive Osteoarthritis Test) - This instrument consists of four items measured on 100mm visual analogue scale (VAS) response scales: joint pain, stiffness, difficulties with physical activities, and overall symptoms.</outcome>
      <timepoint>Measured 3 times on day one then daily for a further 6 days.  These outcomes will be measured once a day for a further 6 days.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Paracetamol usage  participants will record paracetamol usage on a daily basis in a study diary.</outcome>
      <timepoint>Measured 3 times on day one then daily for a further 6 days.  These outcomes will be measured once a day for a further 6 days.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>X-ray and clinical evidence of osteoarthritis of the kneesIn good general healthAdequate venous accessParticipants who are medication free or stable on Glucosamine, NSAID (non steroidal anti inflammatory drugs) or Fish Oil treatment for 3 months.Participants of childbearing age who agree to continue using birth control measures for the duration of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>A history of trauma associated with the affected jointRheumatoid or other inflammatory joint conditionsGoutParticipants with a VAS score above 7 at baseline.Participants who have just commenced on a treatment regimen for arthritis Use of corticosteroids (intra-articular or systematic) within 4 weeks prior to baseline and throughout the studyLiver function tests greater than 3 times the upper limit of normal at baselineHistory of alcohol or substance abuseFemale participants who are lactating, pregnant or planning to become pregnantParticipants who have participated in another clinical trial in the last 30 daysParticipants unwilling to comply with the study protocolAny other condition, which in the opinion of the investigators could compromise the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Participants involved in the study will be blinded and study staff (therapists, assessors and clinicians and data analysts) will be blinded</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>30/05/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Blackmore's Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Blackmore's Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine the efficacy of Evogen® Topical gel in relieving pain in participants with diagnosed osteoarthritis of the knee.  The study hypothesies that the application of Evogen® Topical gel four times a day for 1 week will produce a 50% reduction in pain level.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NatMed-Research Department fo Natural and Complementary Medicine Southern Cross University</ethicname>
      <ethicaddress>Lismore NSW</ethicaddress>
      <ethicapprovaldate>16/04/2007</ethicapprovaldate>
      <hrec>ECN-07-35</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Joan O'Connor</name>
      <address>NatMed-Research
Department of Natural and Complementary Medicine
Southern Cross University
Military Road
Lismore NSW 2480</address>
      <phone>+61 2 66203649</phone>
      <fax>+61 2 66203307</fax>
      <email>joconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Joan O'Connor</name>
      <address>NatMed-Research
Department of Natural and Complementary Medicine
Southern Cross University
Military Road
Lismore NSW 2480</address>
      <phone>+61 2 66203649</phone>
      <fax>+61 2 66203307</fax>
      <email>joconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>